T. Weller

发表

Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.

L. Prade, A. Treiber, S. Delahaye, 2009, Journal of medicinal chemistry.

New classes of potent and bioavailable human renin inhibitors.

L. Prade, A. Treiber, S. Delahaye, 2009, Bioorganic & medicinal chemistry letters.

L. Prade, D. Bur, W. Fischli, 2008 .

Pharmacology of the Urotensin-II Receptor Antagonist ACT-058362: First Demonstration of a Pathophysiological Role of the Urotensin System

M. Clozel, O. Nayler, M. Scherz, 2004 .

Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System

M. Clozel, O. Nayler, M. Scherz, 2004, Journal of Pharmacology and Experimental Therapeutics.

Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines.

P. Hadváry, D. Knopp, S. Bunting, 1996, Journal of medicinal chemistry.

Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor.

P. Hadváry, D. Kirchhofer, L. Jennings, 1992, Blood.

Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

M. Bolli, M. Iglarz, M. Clozel, 2008, Journal of Pharmacology and Experimental Therapeutics.

The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.

M. Bolli, M. Iglarz, M. Clozel, 2012, Journal of medicinal chemistry.

Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2.

R. Koberstein, T. Weller, T. Sifferlen, 2013, Bioorganic & medicinal chemistry letters.

Synthesis, structure-activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1.

R. Koberstein, T. Weller, T. Sifferlen, 2013, Bioorganic & medicinal chemistry letters.

Novel pyrazolo-tetrahydropyridines as potent orexin receptor antagonists.

R. Koberstein, T. Weller, T. Sifferlen, 2010, Bioorganic & medicinal chemistry letters.

Conformationally restricted analogs of platelet-activating factor (PAF)

P. Hadváry, T. Weller, 1986 .

Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.

J. Marfurt, M. Bolli, É. Thorin, 2004, Journal of medicinal chemistry.

Pharmacokinetics, Pharmacodynamics and Tolerability of a Potent, Non-peptidic, GP IIb/IIIa Receptor Antagonist following Multiple Oral Administrations of a Prodrug Form

S. Bunting, M. Beresini, K. Robarge, 1998, Thrombosis and Haemostasis.

Novel S1P1 receptor agonists--part 1: From pyrazoles to thiophenes.

M. Bolli, Stefan Abele, A. Treiber, 2013, Journal of medicinal chemistry.

Low molecular weight, non-peptide fibrinogen receptor antagonists.

P. Hadváry, A. Trzeciak, D. Knopp, 1992, Journal of medicinal chemistry.

Sannamycin‐type aminoglycoside antibiotics of natural and non‐natural (mirror‐image) configuration — total syntheses and biological activity

L. Knothe, H. Prinzbach, K. Pelz, 1995 .

Novel S1P1 receptor agonists - Part 5: From amino-to alkoxy-pyridines.

R. de Kanter, M. Bolli, C. Kohl, 2016, European journal of medicinal chemistry.

Bis-sulfonamides as endothelin receptor antagonists.

M. Bolli, M. Clozel, W. Fischli, 2003, Bioorganic & medicinal chemistry letters.

The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists.

M. Bolli, M. Clozel, P. Hess, 2003, Bioorganic & medicinal chemistry letters.

Novel S1P1 receptor agonists - Part 4: Alkylaminomethyl substituted aryl head groups.

R. de Kanter, M. Bolli, C. Kohl, 2016, European journal of medicinal chemistry.

a potent and selective peptidomimetic inhibitor Reversible conformational changes induced in glycoprotein IIb-IIIa by

P. Hadváry, D. Kirchhofer, B. Steiner, 2011 .

Diastereoselective Synthesis of-Nitro- and-Aminoalcohols

D. Seebach, A. Beck, T. Weller, 1981 .

Design and Scale-Up of a Practical Enantioselective Route to 5-Phenylbicyclo[2.2.2]oct-5-en-2-one

Stefan Abele, T. Weller, R. Inauen, 2012 .

2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists.

M. Bolli, Stefan Abele, A. Treiber, 2010, Journal of medicinal chemistry.

2, 3-Disubstituted γ-Butyrolactams from the Michael-Additions of Doubly Deprotonated, Optically Active β-Hydroxycarboxylates to Nitroolefins. Preliminary Communication

D. Seebach, T. Weller, Max F. Züger, 1980 .

NITROALIPHATIC COMPOUNDS ‐ IDEAL INTERMEDIATES IN ORGANIC SYNTHESIS?

D. Seebach, T. Weller, E. W. Colvin, 1979 .

Simple preparation of a useful c/d-ring fragment for the construction of 11-keto steroids

T. Weller, G. Stork, G. Clark, 1984 .

Synthesis of (±)-1-desoxy-2-lycorinone and of a possible trans-dihydro-lycoricidine precursor

D. Seebach, T. Weller, 1982 .

Total syntheses of enantiomerically pure D- and L-glycosyl donors as components of sannamycin-type aminoglycoside antibiotics

H. Prinzbach, C. Ludin, C. Hoenke, 1994 .

Inhibitors of aspartic proteases – potential antimalarial agents

Olivier Corminboeuf, C. Grisostomi, T. Weller, 2006 .

Aminoglycoside antibiotics ― Enantiomerically pure sporamine building blocks

L. Knothe, H. Prinzbach, C. Ludin, 1989 .

Novel S1P(1) receptor agonists--part 3: from thiophenes to pyridines.

R. de Kanter, M. Bolli, Stefan Abele, 2014, Journal of medicinal chemistry.

The TDE sulfenyl group as a protective group for amines

T. Netscher, T. Weller, 1991 .

Promotion of sleep by targeting the orexin system in rats, dogs and humans

J. V. Gerven, M. Clozel, J. Dingemanse, 2007, Nature Medicine.

Discovery and Characterization of ACT‐451840: an Antimalarial Drug with a Novel Mechanism of Action

R. Brun, S. Delahaye, S. Wittlin, 2016, ChemMedChem.

Fibrinogen receptor antagonists - a novel class of promising antithrombotics

L. Alig, M. Müller, B. Steiner, 1994 .

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling

R. Price, D. Fidock, R. Sinden, 2016, PLoS medicine.

Orexin Receptor Antagonism: A New Principle in Neuroscience

R. Koberstein, T. Weller, T. Sifferlen, 2008 .

Tetrahydroisoquinolines as orexin receptor antagonists: Strategies for lead optimization by solution-phase chemistry

M. Clozel, A. Treiber, O. Nayler, 2003 .

Achiral, Cheap, and Potent Inhibitors of Plasmepsins I, II, and IV

L. Prade, D. Bur, W. Fischli, 2006, ChemMedChem.

Derivatives substituted 1,2,3,4-tetrahydroisoquinoline

M. Clozel, R. Koberstein, W. Fischli, 2005 .

2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists.

M. Bolli, Stefan Abele, A. Treiber, 2010, Journal of medicinal chemistry.

Novel S1P1 receptor agonists - Part 4: Alkylaminomethyl substituted aryl head groups.

R. de Kanter, M. Bolli, C. Kohl, 2016, European journal of medicinal chemistry.

Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

M. Bolli, M. Iglarz, M. Clozel, 2008, Journal of Pharmacology and Experimental Therapeutics.